Opioid sparing anesthesia for bariatric surgery - Trial PACTR201911712319290
Access comprehensive clinical trial information for PACTR201911712319290 through Pure Global AI's free database. This Phase 3 trial is sponsored by Dr Mona Raafat El Ghamry and is currently Recruiting. The study focuses on Digestive System; Anaesthesia.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Dr Mona Raafat El Ghamry
Dr Mona Eelghamry and Dr Atteia Anwar
Timeline & Enrollment
Phase 3
Jan 01, 1900
Jan 01, 1900
Summary
Obese patients are particularly sensitive to the sedative and respiratory depressive effects of long acting opioids. Many obese patients also have obstructive sleep apnoea syndrome (OSAS) and will be prone to airway obstruction and desaturation in the postoperative period.Dexmedetomidine is a short acting, highly potent, selective ฮฑ2 adrenoceptor agonist with unique analgesic, sedative, amnesic and anaesthesia-sparing properties.Erector spinae plane block could result in both visceral and somatic abdominal analgesia if the injection is performed at a lower thoracic level.The aim of this study is to evaluate the opioid sparing effect of erector spinae plane block and intravenous dexmedetomidine in patients undergoing laparoscopic bariatric surgeries
ICD-10 Classifications
Data Source
Pan Africa Clinical Trials Registry
PACTR201911712319290
Non-Device Trial